Cerebrolysin® is safe and well tolerated!
The experience with Cerebrolysin® during many years of clinical application, the information from post-marketing surveillance studies, and the safety data from double-blind, placebo-controlled clinical trials indicate an extremely high degree of safety (e.g. significat reduction of mortality in CASTA study1).
According to EMA classification, Cerebrolysin® is in the “SAFE” category (PSUR reporting required only every 13 years).
In general, reported adverse drug reactions from Cerebrolysin® treated patients are transient and mild in intensity.
The most frequently reported adverse reactions with Cerebrolysin® are
Please note that the handling is very important. Please find more information in our dosage recommendation.
1 Heiss 2012, Stroke. 43:630-636.